| Bioactivity | VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] . |
| Target | NAPE-PLD activator, with an EC50 of 0.30 μM |
| Invitro | VU534 (高达30 μM, 24 h) 对 HepG2 和 Raw264.7 细胞系的细胞毒性较小 [1]。VU534 (3~30 μM, 1 h) 可提高 Raw264.7 细胞内 NAPE-PLD 活性 [1]。VU534 (1 h) 可提高 HepG2 细胞内 NAPE-PLD 活性，EC50值为1.5 μM[1]。VU534 (5 μM, 1 h) 使 NAPE-PLD 活性增加 1.5 倍，但未逆转 LEI – 401 (HY-131181) 抑制的 NAPE-PLD 活性[1]。VU534 (10 μM, 6 h) 显著增强骨髓来源巨噬细胞的胞葬作用，但在 Napepld 敲除时不能发挥这种作用[1]。 |
| Name | VU534 |
| CAS | 923509-20-0 |
| Formula | C21H22FN3O3S2 |
| Molar Mass | 447.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jonah E Zarrow, et al. Small Molecule Activation of NAPE-PLD Enhances Efferocytosis by Macrophages. ACS Chem. Biol. 2023, 18, 8, 1891–1904. |